Roche Launches Legal Battle Against Biogen

Roche Launches Legal Battle Against Biogen’s Imitative Biosimilar of Blockbuster Arthritis Drug

Roche Launches Legal Battle Against Biogen’s Imitative Biosimilar of Blockbuster Arthritis Drug July 14, 2023  – Roche (ROG.S) and its subsidiary powerhouses have taken a decisive step by initiating legal proceedings against biotech frontrunner Biogen (BIIB.O) in the federal court of Massachusetts. Their grievance centers around Biogen’s audacious attempt to replicate Roche’s highly successful drug…

Roche receives FDA clearance for additional Alzheimer’s

Roche receives FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Roche, a leading biotechnology company, has obtained clearance from the U.S. Food and Drug Administration (FDA) for other Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. The newly cleared assays, known as Elecsys tTau/Abeta42 ratio, are crucial in enabling timely diagnosis and facilitating treatment decisions for Alzheimer’s disease. The Elecsys tTau/Abeta42 ratio is designed to assist clinicians…